Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition

Regulus Therapeutics drug farabursen is a potential first-in-class treatment for a rare kidney disease whose only FDA-approved therapy introduces severe toxicity risks. Farabursen is joining a Novartis drug lineup spanning several therapies for rare renal disorders. The post Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition appeared first on MedCity News.

Read More

Help Us Investigate Medical Care for Gunshot Wounds

KFF Health News and The Trace are teaming up to take a deep look at how insurance status affects treatment for gunshot wounds. We’re looking for survivors, their friends and family, or family members of people who suffered complications or died from gunshot wounds after leaving the hospital. We want to hear about medical treatment,…

Read More

Health Provisions in the 2025 Federal Budget Reconciliation Law

On July 4, President Trump signed the budget reconciliation bill, previously known as the “One Big Beautiful Bill Act,” into law. This summary provides background, description, budgetary impact and related information on the health care provisions of the law in four categories: Medicaid, the Affordable Care Act, Medicare and Health Savings Accounts (HSAs).

Read More

This Geriatrics Training Program Escaped the Ax. For Now.

In St. Louis, a team of students aboard a well-equipped van visits senior centers, a nursing home, a church, and other sites, learning to conduct comprehensive, hourlong geriatric assessments. The team — future doctors, social workers, psychologists, and therapists — looks for such common problems as frailty, muscle weakness, and cognitive decline. The patients they…

Read More